P74. A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukaemic virus-specific T-cells
MM van Loenen, R de Boer, E van Liempt, RS Hagedoorn, P Meij, I Jedema, JHF Falkenburg, MHM Heemskerk
Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P48; DOI: 10.1186/2051-1426-2-S2-P48